CO5450243A1 - Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion - Google Patents
Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacionInfo
- Publication number
- CO5450243A1 CO5450243A1 CO03035403A CO03035403A CO5450243A1 CO 5450243 A1 CO5450243 A1 CO 5450243A1 CO 03035403 A CO03035403 A CO 03035403A CO 03035403 A CO03035403 A CO 03035403A CO 5450243 A1 CO5450243 A1 CO 5450243A1
- Authority
- CO
- Colombia
- Prior art keywords
- derivative
- alkyl
- formula
- heterocycle
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
Compuesto que tiene la fórmula l o una de sus sales farmacéuticamente aceptables, <EMI FILE="03035403_1" ID="1" IMF=JPEG >En la cualX es N o CH;R1 es cicloalquilo, arilo, heterociclo, aralquilo, heterociclo-alquilo, o un oxi-derivado, o un grupo de fórmula: <EMI FILE="03035403_2" ID="2" IMF=JPEG >R2 es -NR4R5, -OR4 o -C(=O)NR5R6;R3 es tetrazol, -CN, -CH2OH o -CO-R7R4 es H, -G1-R8, o un grupo de fórmula: <EMI FILE="03035403_3" ID="3" IMF=JPEG >R5 es H, C1-4-alquilo; o -NR4R5 representa un heterociclo o -N=CR9R10; R6 es arilo, heterociclo, cicloalquilo o aralquilo;R7 es hidroxi, amino, hidroxilamino, un oxi-derivado o un amino-derivado;G1 es CO, CH2, SO2;R8 es arilo, heterociclo, cicloalquilo, aralquilo o -NH-arilo.R9 es arilo; yR10 es éter;Con la condición de que cuando x es CH, R1 es cicloalquilo o un oxi-derivado de fórmula -O-Ra en la cual Ra es C1-6-alquilo, un fenilo opcionalmente sustituido o trifluorometilo R2 es -NR4R5, R3 es CO-R7, R4 es H o G1-R8, R5 es H, C1-4-alquilo, G1 es CO, CH2, SO2, R8 es un grupo fenilo opcionalmente sustituido, cicloalquilo o -NH-fenilo (un opcionalmente sustituido), entonces R7 no es un oxi-derivado de fórmula -O-CHRbRc en la cual Rb es H, C1-6- alquilo o un fenilo opcionalmente sustituido y RC es un fenilo opcionalmente sustituido, o un amino-derivado de fórmula -NRd-CHRbRc en la cual Rb y RC tienen las mismas definiciones que se han descrito anteriormente, y Rd es H o C1-6-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02009746 | 2002-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5450243A1 true CO5450243A1 (es) | 2004-10-29 |
Family
ID=29286106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03035403A CO5450243A1 (es) | 2002-04-30 | 2003-04-29 | Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7638630B2 (es) |
| EP (2) | EP1501801B1 (es) |
| JP (1) | JP2005535583A (es) |
| KR (1) | KR100841165B1 (es) |
| CN (2) | CN1649842A (es) |
| AR (1) | AR039341A1 (es) |
| AT (1) | ATE384699T1 (es) |
| AU (1) | AU2003232472B2 (es) |
| BR (1) | BR0309719A (es) |
| CA (1) | CA2484954C (es) |
| CO (1) | CO5450243A1 (es) |
| CU (1) | CU23415B7 (es) |
| DE (1) | DE60318839T2 (es) |
| ES (1) | ES2298543T3 (es) |
| IL (1) | IL164516A0 (es) |
| MX (1) | MXPA04010673A (es) |
| MY (1) | MY135218A (es) |
| NO (1) | NO20045234L (es) |
| NZ (1) | NZ536180A (es) |
| PL (1) | PL373763A1 (es) |
| RU (1) | RU2315041C2 (es) |
| TW (2) | TWI268278B (es) |
| WO (1) | WO2003093237A1 (es) |
| ZA (1) | ZA200408447B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649842A (zh) * | 2002-04-30 | 2005-08-03 | Ucb公司 | 2,6－喹啉基和2,6－萘基衍生物、用于制备它们的方法和它们作为vla－4抑制剂的用途 |
| US7153889B2 (en) | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| CN101386600B (zh) * | 2003-02-20 | 2011-07-06 | 味之素株式会社 | 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体 |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7145005B2 (en) | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| JP2008542407A (ja) * | 2005-06-09 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用 |
| CA2668596A1 (en) | 2006-11-14 | 2008-05-22 | Santen Pharmaceutical Co., Ltd. | Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
| WO2008125215A1 (en) * | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| WO2008125210A1 (en) * | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases |
| WO2008138592A1 (en) * | 2007-05-14 | 2008-11-20 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| WO2008138615A1 (en) * | 2007-05-16 | 2008-11-20 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| MX2010006110A (es) * | 2007-12-12 | 2010-06-25 | Astrazeneca Ab | Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i. |
| EP2085407A1 (en) | 2008-02-04 | 2009-08-05 | Sahltech I Göteborg AB | Treatment of idiopathic thrombocytopenic purpura |
| JP5635743B2 (ja) | 2008-05-12 | 2014-12-03 | 参天製薬株式会社 | 置換オキシ基を有する２，２，４−トリメチル−６−フェニル−１，２−ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト |
| EP2467159A1 (en) | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| WO2015196086A1 (en) * | 2014-06-20 | 2015-12-23 | The University of Montana, Missoula, MT | NOVEL INHIBITORS OF SYSTEM Xc(-) |
| MY189770A (en) * | 2014-12-24 | 2022-03-04 | Lg Chemical Ltd | Biaryl derivative as gpr120 agonists |
| CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
| WO2022162164A1 (en) | 2021-01-29 | 2022-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2920741B2 (ja) * | 1994-12-14 | 1999-07-19 | 参天製薬株式会社 | 新規１，３−ジアルキルウレア誘導体 |
| WO1996018606A1 (fr) | 1994-12-14 | 1996-06-20 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives 1,3-dialkyluree |
| JPH0987291A (ja) | 1995-09-26 | 1997-03-31 | Wakamoto Pharmaceut Co Ltd | 新規なアラニン誘導体 |
| EP0977989A1 (en) | 1997-02-04 | 2000-02-09 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
| CA2301377C (en) * | 1997-08-22 | 2009-10-06 | F. Hoffmann-La Roche Ag | N-aroylphenylalanine derivatives |
| KR20010085630A (ko) * | 1998-08-26 | 2001-09-07 | 앤드류 앵뉴 | 세포 접착 억제를 조절하는 아자-비사이클 |
| EP1175412A1 (en) | 1999-04-28 | 2002-01-30 | Dr. Reddy's Research Foundation | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| US6280442B1 (en) * | 1999-09-01 | 2001-08-28 | Sdgi Holdings, Inc. | Multi-axial bone screw assembly |
| US6399599B1 (en) * | 1999-10-13 | 2002-06-04 | Novartis Ag | Substituted 2-oxo-1,4-diazacycloalkanes |
| CN1649842A (zh) * | 2002-04-30 | 2005-08-03 | Ucb公司 | 2,6－喹啉基和2,6－萘基衍生物、用于制备它们的方法和它们作为vla－4抑制剂的用途 |
| JP2008542407A (ja) | 2005-06-09 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用 |
-
2003
- 2003-04-15 CN CNA038097907A patent/CN1649842A/zh active Pending
- 2003-04-15 AU AU2003232472A patent/AU2003232472B2/en not_active Ceased
- 2003-04-15 PL PL03373763A patent/PL373763A1/xx not_active Application Discontinuation
- 2003-04-15 EP EP03747411A patent/EP1501801B1/en not_active Expired - Lifetime
- 2003-04-15 CA CA2484954A patent/CA2484954C/en not_active Expired - Fee Related
- 2003-04-15 EP EP07017712A patent/EP1870402A1/en not_active Withdrawn
- 2003-04-15 NZ NZ536180A patent/NZ536180A/en not_active IP Right Cessation
- 2003-04-15 RU RU2004135304/04A patent/RU2315041C2/ru not_active IP Right Cessation
- 2003-04-15 CN CNA2007101934884A patent/CN101200450A/zh active Pending
- 2003-04-15 AT AT03747411T patent/ATE384699T1/de not_active IP Right Cessation
- 2003-04-15 ES ES03747411T patent/ES2298543T3/es not_active Expired - Lifetime
- 2003-04-15 BR BR0309719-6A patent/BR0309719A/pt not_active IP Right Cessation
- 2003-04-15 WO PCT/EP2003/003909 patent/WO2003093237A1/en active IP Right Grant
- 2003-04-15 US US10/513,347 patent/US7638630B2/en not_active Expired - Fee Related
- 2003-04-15 DE DE60318839T patent/DE60318839T2/de not_active Expired - Lifetime
- 2003-04-15 KR KR1020047017498A patent/KR100841165B1/ko not_active IP Right Cessation
- 2003-04-15 JP JP2004501376A patent/JP2005535583A/ja not_active Ceased
- 2003-04-15 MX MXPA04010673A patent/MXPA04010673A/es active IP Right Grant
- 2003-04-23 AR ARP030101389A patent/AR039341A1/es unknown
- 2003-04-25 TW TW094147669A patent/TWI268278B/zh active
- 2003-04-25 TW TW092109709A patent/TWI267508B/zh not_active IP Right Cessation
- 2003-04-29 CO CO03035403A patent/CO5450243A1/es not_active Application Discontinuation
- 2003-04-29 MY MYPI20031612A patent/MY135218A/en unknown
-
2004
- 2004-10-12 IL IL16451604A patent/IL164516A0/xx unknown
- 2004-10-19 ZA ZA200408447A patent/ZA200408447B/en unknown
- 2004-11-01 CU CU20040252A patent/CU23415B7/es not_active IP Right Cessation
- 2004-11-29 NO NO20045234A patent/NO20045234L/no unknown
-
2009
- 2009-10-23 US US12/604,959 patent/US20100105681A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5450243A1 (es) | Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion | |
| AR109033A2 (es) | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso | |
| RS52931B (en) | VIRAL POLYMERASE INHIBITORS | |
| TR200000447T2 (tr) | 5-Alkil-2-arilaminofenilasetik asitler ve türevleri. | |
| CO5700820A2 (es) | Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| RS50540B (sr) | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| DE60300824D1 (de) | Laserprojektionssystem | |
| DE602004016353D1 (de) | Dentalzusammensetzungen und verfahren mit arylsulfinatsalzen | |
| EA200400987A1 (ru) | Трипептиды, несущие простой гидроксипролиновый эфир замещённого хинолина, предназначенные для ингибирования протеазы ns3 (гепатит c) | |
| DK1505998T3 (da) | Forbedret anvendelse af hop-syrer som antimikrobielle midler | |
| PA8654501A1 (es) | Derivados de quinazolina inhibidores de quinasas dirigidos a multiples blancos | |
| ATE302775T1 (de) | Carbolinderivate | |
| DE602004012448D1 (de) | Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus | |
| AR041256A1 (es) | Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6 | |
| NO20031185D0 (no) | Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel | |
| ATE251117T1 (de) | Neue aminobenzophenone | |
| UY28375A1 (es) | Agente terapéuticos | |
| AR014714A1 (es) | Sales de cetoacidos y derivados de aminas, y su utilizacion para la preparacion de medicamentos | |
| DE602004026242D1 (de) | Derivate von alkalischen Aminosäuren als Geliermitteln | |
| EA200401482A1 (ru) | Ненуклезидные ингибиторы обратной транскриптазы | |
| EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200600898A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
| CO5261505A1 (es) | Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |